Figure 3
From: Suppression of endothelial cell activity by inhibition of TNFα
Certolizumab pegol inhibits HL-60 cell-human dermal microvascular endothelial cell adhesion induced by TNFα. TNFα-stimulated adhesion-molecule-mediated human promyelocytic leukemia (HL-60) cell-human dermal microvascular endothelial cell (HMVEC) adhesion is blocked by certolizumab pegol. Adhesion assays were performed using HL-60 cells and TNFα-preincubated HMVECs in the presence of anti-E-selectin or anti-intercellular adhesion molecule-1 (anti-ICAM-1) or anti-vascular cell adhesion molecule-1 (anti-VCAM-1) antibody, or of different concentrations of certolizumab pegol or mouse-IgG (Ms-Ig) control for 8 hours. (A) TNFα (25 ng/ml) significantly induces HL-60 adhesion to HMVECs, and anti-E-selectin but not anti-ICAM-1 or anti-VCAM-1 antibody block this interaction (*P < 0.05). (B) HL-60 cell adhesion to HMVECs is significantly inhibited by certolizumab pegol (0.005 to 1 μg/ml, from 10 to 57% of TNFα-induced binding; *P < 0.05). Results are presented as the percentage of TNFα-induced adhesion ± standard error of the mean. n, number of individual experiments. NS, nonstimulated.